Verition Fund Management
RXRX icon

Verition Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Verition Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Hold
412,747
– – 0.01% 1215
2025
Q4 		$1.69M Buy
412,747
+358,169
+656% +$1.77M 0.01% 1760
2025
Q3 		$266K Sell
54,578
-168,638
-76% -$886K ﹤0.01% 3351
2025
Q2 		$1.13M Buy
223,216
+113,703
+104% +$559K 0.01% 2381
2025
Q1 		$579K Buy
+109,513
New +$798K ﹤0.01% 2492
2023
Q2 		– Sell
-33,400
Closed -$223K – 2492
2023
Q1 		$223K Buy
+33,400
New +$265K ﹤0.01% 1705

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Verition Fund Management's RXRX Position: Q1 2026 in Review

Verition Fund Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 412,747 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #1215.

Verition Fund Management first reported a position in RXRX in Q1 2023 and has held it in 6 quarters since. The position peaked at $1.69M in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Verition Fund Management held 412,747 shares of Recursion Pharmaceuticals worth $1.27M as of Q1 2026.
  • Verition Fund Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q1 2026, its #1215 holding.
  • Verition Fund Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Verition Fund Management's Recursion Pharmaceuticals position peaked at $1.69M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.